Literature DB >> 20011562

Accomplishments in 2008 in the management of hepatobiliary cancers.

Andrew X Zhu1, Anthony El-Khoueiry, Josep M Llovet.   

Abstract

HEPATOCELLULAR CARCINOMA: EpidemiologyManagement of HCC-Standard Approaches and Reports During the Past Year SurgeryLocoregional Treatment Local AblationChemoembolizationOther Local Treatment ModalitiesSystemic TreatmentClinical Trial DesignBasic Science and Biomarkers Basic and Translational SciencePrognostic and Predictive Markers Prognostic MarkersPredictive MarkersAccomplishments and Future DirectionsApplication of the AccomplishmentsFuture Directions BILIARY TRACT CANCERS: Overview of the DiseaseManagement of Biliary Tract Cancers-Current Approaches and Reports During the Past Year Surgical Resection and Adjuvant TherapySystemic Therapy for Unresectable or Metastatic Biliary Tract Cancer Cytotoxic ChemotherapyCytotoxic Chemotherapy in Combination With Targeted AgentSingle-Agent Targeted TherapyCombination of Targeted AgentsBiologyFuture Directions.

Entities:  

Year:  2009        PMID： 20011562      PMCID： PMC2791389     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


  53 in total

Review 1.  Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score).

Authors:  Masatoshi Kudo; Hobyung Chung; Yukio Osaki
Journal:  J Gastroenterol       Date:  2003       Impact factor: 7.527

Review 2.  Resection and liver transplantation for hepatocellular carcinoma.

Authors:  Josep M Llovet; Myron Schwartz; Vincenzo Mazzaferro
Journal:  Semin Liver Dis       Date:  2005       Impact factor: 6.115

3.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

4.  The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma.

Authors:  Lei Chen; He-Xin Yan; Wen Yang; Liang Hu; Le-Xin Yu; Qiong Liu; Liang Li; Dan-Dan Huang; Jin Ding; Feng Shen; Wei-Ping Zhou; Meng-Chao Wu; Hong-Yang Wang
Journal:  J Hepatol       Date:  2008-11-21       Impact factor: 25.083

5.  Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.

Authors:  Abby B Siegel; Emil I Cohen; Allyson Ocean; Deborah Lehrer; Alec Goldenberg; Jennifer J Knox; Helen Chen; Sean Clark-Garvey; Alan Weinberg; John Mandeli; Paul Christos; Madhu Mazumdar; Elizabeta Popa; Robert S Brown; Shahin Rafii; Jonathan D Schwartz
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

6.  Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis.

Authors:  Laura M Kulik; Brian I Carr; Mary F Mulcahy; Robert J Lewandowski; Bassel Atassi; Robert K Ryu; Kent T Sato; Al Benson; Albert A Nemcek; Vanessa L Gates; Michael Abecassis; Reed A Omary; Riad Salem
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

7.  High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma.

Authors:  Xiao-Dong Zhu; Ju-Bo Zhang; Peng-Yuan Zhuang; Hong-Guang Zhu; Wei Zhang; Yu-Quan Xiong; Wei-Zhong Wu; Lu Wang; Zhao-You Tang; Hui-Chuan Sun
Journal:  J Clin Oncol       Date:  2008-06-01       Impact factor: 44.544

8.  Pivotal role of mTOR signaling in hepatocellular carcinoma.

Authors:  Augusto Villanueva; Derek Y Chiang; Pippa Newell; Judit Peix; Swan Thung; Clara Alsinet; Victoria Tovar; Sasan Roayaie; Beatriz Minguez; Manel Sole; Carlo Battiston; Stijn Van Laarhoven; Maria I Fiel; Analisa Di Feo; Yujin Hoshida; Steven Yea; Sara Toffanin; Alex Ramos; John A Martignetti; Vincenzo Mazzaferro; Jordi Bruix; Samuel Waxman; Myron Schwartz; Matthew Meyerson; Scott L Friedman; Josep M Llovet
Journal:  Gastroenterology       Date:  2008-08-20       Impact factor: 22.682

9.  Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

Authors:  Yujin Hoshida; Augusto Villanueva; Masahiro Kobayashi; Judit Peix; Derek Y Chiang; Amy Camargo; Supriya Gupta; Jamie Moore; Matthew J Wrobel; Jim Lerner; Michael Reich; Jennifer A Chan; Jonathan N Glickman; Kenji Ikeda; Masaji Hashimoto; Goro Watanabe; Maria G Daidone; Sasan Roayaie; Myron Schwartz; Swan Thung; Helga B Salvesen; Stacey Gabriel; Vincenzo Mazzaferro; Jordi Bruix; Scott L Friedman; Hiromitsu Kumada; Josep M Llovet; Todd R Golub
Journal:  N Engl J Med       Date:  2008-10-15       Impact factor: 91.245

10.  Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling.

Authors:  Yi Tang; Krit Kitisin; Wilma Jogunoori; Cuiling Li; Chu-Xia Deng; Susette C Mueller; Habtom W Ressom; Asif Rashid; Aiwu Ruth He; Jonathan S Mendelson; John M Jessup; Kirti Shetty; Michael Zasloff; Bibhuti Mishra; E P Reddy; Lynt Johnson; Lopa Mishra
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-08       Impact factor: 11.205
View more
  2 in total

1.  Cost-effectiveness of gemcitabine + cisplatin vs. gemcitabine monotherapy in advanced biliary tract cancer.

Authors:  Joshua A Roth; Josh J Carlson
Journal:  J Gastrointest Cancer       Date:  2012-06

2.  Perfusion reduction at transcatheter intraarterial perfusion MR imaging: a promising intraprocedural biomarker to predict transplant-free survival during chemoembolization of hepatocellular carcinoma.

Authors:  Dingxin Wang; Ron C Gaba; Brian Jin; Robert J Lewandowski; Ahsun Riaz; Khairuddin Memon; Robert K Ryu; Kent T Sato; Laura M Kulik; Mary F Mulcahy; Andrew C Larson; Riad Salem; Reed A Omary
Journal:  Radiology       Date:  2014-03-28       Impact factor: 11.105
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.